secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001213900-24-098380
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio completes randomization of 208 patients in Phase 2 Alzheimer's trial; top-line data Q2 2025
--------------------------------------------------------------------------------

- Total of 208 patients enrolled, exceeding target; 56% mild AD and 44% MCI.
- Top-line cognitive results expected in Q2 2025 for the Phase 2 AD02 trial.
- Trial uses XPro to target glial-driven neuroinflammation in early Alzheimer's.
- Global, blinded, randomized Phase 2 trial; first doses administered to all patients.
- CEO RJ Tesi cited overenrollment as a major accomplishment for the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390024098380/0001213900-24-098380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390024098380/ea0221033-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-098380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer